美股市場個股詳情

RCUS Arcus Biosciences

添加自選

15.530
+0.030+0.19%

交易中 05/02 09:40 (美東)

14.12億總市值-3742市盈率TTM

Arcus Biosciences股票討論區

登錄發表評論

Meltyy

04/03 11:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

Moomoo AI

03/22 18:31

The recent sale of Arcus Biosciences shares by the COO and the lack of insider buying over the last year raises caution. The level of insider ownership indicates some alignment between management and smaller shareholders, but it's not particularly high.

Arcus Biosciences Chief Operating Officer Jennifer Jarrett Sells 27% Of Holding

Moomoo AI

02/23 18:42

Despite a moderate P/S ratio, the company's revenue growth lags behind others, potentially problematic if the trend persists. Muted future growth estimates compared to the industry could lead to disappointment if the P/S aligns with the growth outlook.

Optimistic Investors Push Arcus Biosciences, Inc. (NYSE:RCUS) Shares Up 27% But Growth Is Lacking

Moomoo AI

02/13 18:49

Arcus Biosciences' cash runway is promising despite a significant drop in revenue. However, shareholders may face costly dilution if the company sells shares to cover another year's operations. The falling revenue is concerning for the cash burning company.

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Moomoo AI

2023/11/12 20:33

Despite the weaker earnings outlook, the consensus price target suggests analysts do not anticipate a long-term impact on the company’s valuation. However, the downgrade of next year's forecast instills caution regarding Arcus Biosciences' future performance.

Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts

Moomoo AI

2023/10/29 22:51

Arcus Biosciences' falling revenue is concerning despite its reassuring cash runway. Though the forecast of reaching breakeven soon is positive, the potential for share dilution due to further cash raising is a risk for shareholders.

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

逍遥投资派

2023/01/15 17:47

$Arcus Biosciences(RCUS.US)$营收近两年大涨，2021年更是达到了3.8亿，营业利润2021年扭亏达到0.54亿，净利润达到0.53亿。
2022前三季度营收增长1.8倍到0.8亿，营业利润亏损缩小至2.1亿，净利润亏损缩小至2亿，全年利润完全看第四季度的表现，目前很难评估其投资价值。

Moomoo Breakfast US

2022/08/09 20:38

專欄Today's pre-market stock movers: NVAX, MRNA, NCLH, MU and more

Gainers:
In reaction to earnings/guidance:
• $GoodRx(GDRX.US)$ +38.5%,$EDGIO(EGIO.US)$ +13.5%,$Lemonade(LMND.US)$ +10.7%,$Desktop Metal(DM.US)$ +8.5%,$ShockWave Medical(SWAV.US)$ +8.2%,$Pubmatic(PUBM.US)$ +8.1%,$Olaplex(OLPX.US)$ +7%,$Vivid Seats(SEAT.US)$ +6.4%,$Noble(NE.US)$ +6.3%,$艾斯本科技(AZPN.US)$ +5.4%,$艾倫建材(AAON.US)$ +5%,$Hudbay Minerals(HBM.US)$ +5%,$Vivint Smart Home(VVNT.US)$ +4.9%,$Vivint Smart Home(VVNT.US)$ +4...

Moomoo Breakfast US

2022/04/05 20:31

專欄Today's pre-market stock movers: RCUS, ANY, CGNT, XPOF and more

Gainers:
• $Arcus Biosciences(RCUS.US)$ +11.2% (appointed to join S&P SmallCap 600)
• $Sphere 3d(ANY.US)$ +10.13% (mutually agreed to terminate merger agreement with Gryphon Digital Mining)
• $Theravance Biopharma(TBPH.US)$ +3.05% (announced results from Study 0170)
• $嘉年華存託憑證(CUK.US)$ +4.7% (reported that March 28-April 3 was the busiest booking week in company history)
• $Castle Biosciences(CSTL.US)$ +4.4% (agreed to acquire Althe...

OldNormanBates

2021/06/25 17:58

$Arcus Biosciences(RCUS.US)$ Holding My New Position....

曬曬你今日的盈虧

暫無評論

分析

分析師評級

暫無數據

目標價預測

暫無數據

熱議

美股

綜合熱度